Skip to main content
Equibles

Anula Jayasuriya

Board Member

Jaguar Health, Inc. (JAGX)

Board Member

Lineage Cell Therapeutics, Inc. (LCTX)

Equibles does not estimate personal net worth.

Get an email with a short summary when Jaguar Health, Inc. publishes a filing, an earnings call transcript or a press release.

Get JAGX alerts

About Anula Jayasuriya

Anula Jayasuriya is recorded as Board Member at Jaguar Health, Inc. (JAGX) and Board Member at Lineage Cell Therapeutics, Inc. (LCTX) since January 1, 2021. The newest filing on record that lists Anula Jayasuriya as Board Member at Jaguar Health, Inc. (JAGX) is dated April 30, 2026. The newest filing on record that lists Anula Jayasuriya as Board Member at Lineage Cell Therapeutics, Inc. (LCTX) is dated April 29, 2026. Lineage Cell Therapeutics, Inc. reported in an 8-K filed September 7, 2023 that Anula Jayasuriya was appointed director, effective September 6, 2023. Jaguar Health, Inc. reported in an 8-K filed July 6, 2022 that Anula Jayasuriya was appointed Class III director, effective July 1, 2022. Jaguar Health, Inc. is classified in the Biotechnology industry within the Healthcare sector. Lineage Cell Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Jaguar Health, Inc. includes Lisa A. Conte (CEO and Board Member), James J. Bochnowski (Chairman), Carol Lizak (CFO and Chief Accounting Officer) and 4 others.

“The Company’s shareholders elected the nine nominees named below to the Company’s board of directors to hold office until the Company’s 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Lineage Cell Therapeutics, Inc. Form 8-K, filed September 7, 2023 · Read the filing
“On July 1, 2022, the Board, by resolution as contemplated in the Company's bylaws, appointed Dr. Anula Jayasuriya to fill the vacancy created by Mr. Divis's resignation and serve as Class III director of the Company until (i) the 2024 Annual Meeting of Stockholders of the Company and her successor has been duly elected and qualified or (ii) her death, resignation or removal, whichever is earlier.”
Jaguar Health, Inc. Form 8-K, filed July 6, 2022 · Read the filing

Affiliation history

Company network

Leadership on record at Jaguar Health, Inc.

Leadership on record at Lineage Cell Therapeutics, Inc.

Recent activity